NASDAQ:IONS - Ionis Pharmaceuticals Stock Price, Price Target & More

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

Ionis Pharmaceuticals Inc (NASDAQ:IONS) issued its earnings results on Friday, May, 4th. The company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.10. The company had revenue of $144.40 million for the quarter, compared to the consensus estimate of $144.01 million. Ionis Pharmaceuticals had a negative net margin of 2.00% and a negative return on equity of 3.06%. The firm's revenue for the quarter was up 24.7% on a year-over-year basis. During the same period in the previous year, the firm earned $0.03 earnings per share. View Ionis Pharmaceuticals' Earnings History.

11 brokerages have issued 1-year price objectives for Ionis Pharmaceuticals' shares. Their predictions range from $18.00 to $75.00. On average, they anticipate Ionis Pharmaceuticals' share price to reach $53.00 in the next twelve months. This suggests a possible upside of 15.6% from the stock's current price. View Analyst Ratings for Ionis Pharmaceuticals.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 3 sell ratings, 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

Some companies that are related to Ionis Pharmaceuticals include Mylan (MYL), BioMarin Pharmaceutical (BMRN), UCB (UCBJF), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), Ono Pharmaceutical (OPHLF), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), Beigene (BGNE), Nektar Therapeutics (NKTR), Valeant Pharmaceuticals (VRX) and SAGE Therapeutics (SAGE).

Press coverage about IONS stock has been trending somewhat positive this week, Accern reports. The research group identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Ionis Pharmaceuticals earned a coverage optimism score of 0.04 on Accern's scale. They also gave news articles about the company an impact score of 48.56 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Ionis Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (7.39%), Sicart Associates LLC (0.42%), Scout Investments Inc. (0.29%), Peregrine Capital Management LLC (0.26%), BLB&B Advisors LLC (0.20%) and Amalgamated Bank (0.02%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Ionis Pharmaceuticals Inc, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Sarah Boyce, Spencer R Berthelsen and Stanley T Crooke. View Institutional Ownership Trends for Ionis Pharmaceuticals.

IONS stock was sold by a variety of institutional investors in the last quarter, including BLB&B Advisors LLC. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Sarah Boyce, Spencer R Berthelsen and Stanley T Crooke. View Insider Buying and Selling for Ionis Pharmaceuticals.

IONS stock was acquired by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Peregrine Capital Management LLC, Sicart Associates LLC, Scout Investments Inc., State of Alaska Department of Revenue, Amalgamated Bank, Xact Kapitalforvaltning AB and Bank of Montreal Can. View Insider Buying and Selling for Ionis Pharmaceuticals.

Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of IONS stock can currently be purchased for approximately $45.84.

Ionis Pharmaceuticals has a market capitalization of $5.54 billion and generates $507.67 million in revenue each year. The company earns $-5,960,000.00 in net income (profit) each year or $0.08 on an earnings per share basis. Ionis Pharmaceuticals employs 547 workers across the globe.

Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at 760-931-9200.